Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

被引:67
作者
Mohty, Mohamad [1 ]
Labopin, Myriam [2 ,3 ]
Tabrizzi, Reza [4 ]
Theorin, Niklas [5 ]
Fauser, Axel A. [6 ]
Rambaldi, Alessandro [7 ]
Maertens, Johan [8 ]
Slavin, Shimon [9 ]
Majolino, Ignazio [10 ]
Nagler, Arnon [11 ]
Blaise, Didier [12 ]
Rocha, Vanderson [2 ,3 ,13 ]
机构
[1] Univ Nantes, CHU Hotel Dieu, Serv Hematol Clin, Pl Alexis Ricordeau, F-44093 Nantes, France
[2] Hop St Antoine, AP HP, European Grp Blood & Marrow Transplantat EBMT, Acute Leukemia Working Party, Paris, France
[3] Univ Paris 06, Pierre & Marie Curie, Paris, France
[4] CHU Bordeaux, Hop Haut Leveque, Pessac, France
[5] Univ Hosp, Dept Hematol, Linkoping, Sweden
[6] Klin Knochenmarktransplantat & Haematol Onkol, Idar Oberstein, Germany
[7] Osped Bergamo, Div Ematol, Bergamo, Italy
[8] Univ Hosp Gasthuisberg, Dept Hematol, Leuven, Belgium
[9] Hadassah Univ Hosp, Dept Bone Marrow Transplantat, Jerusalem, Israel
[10] Osped S Camillo Forlanini, Dept Hematol & BMT, Rome, Italy
[11] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel
[12] Inst Paoli Calmettes, Unite Transplantat & Therapie Cellulaire, Marseille, France
[13] Hop St Louis, AP HP, Dept Hematol, Paris, France
关键词
allogeneic SCT; acute lymphoblastic leukemia;
D O I
10.3324/haematol.11960
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52 +/- 9%; 42 +/- 10%; and 18 +/- 7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively). In multivariate analysis, disease status (CR1 vs. advanced; p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation.
引用
收藏
页码:303 / 306
页数:4
相关论文
共 20 条
[1]   Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].
Aoudjhane, M ;
Labopin, M ;
Gorin, NC ;
Shimoni, A ;
Ruutu, T ;
Kolb, HJ ;
Frassoni, F ;
Boiron, JM ;
Yin, JL ;
Finke, J ;
Shouten, H ;
Blaise, D ;
Falda, M ;
Fauser, AA ;
Esteve, J ;
Polge, E ;
Slavin, S ;
Niederwieser, D ;
Nagler, A ;
Rocha, V .
LEUKEMIA, 2005, 19 (12) :2304-2312
[2]   Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease [J].
Arnold, R ;
Massenkeil, G ;
Bornhäuser, M ;
Ehninger, G ;
Beelen, DW ;
Fauser, AA ;
Hegenbart, U ;
Hertenstein, B ;
Ho, AD ;
Knauf, W ;
Kolb, HJ ;
Kolbe, K ;
Sayer, HG ;
Schwerdtfeger, R ;
Wandt, H ;
Hoelzer, D .
LEUKEMIA, 2002, 16 (12) :2423-2428
[3]   CHEMOTHERAPY COMPARED WITH BONE-MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN 1ST REMISSION [J].
HOROWITZ, MM ;
MESSERER, D ;
HOELZER, D ;
GALE, RP ;
NEISS, A ;
ATKINSON, K ;
BARRETT, AJ ;
BUCHNER, T ;
FREUND, M ;
HEIL, G ;
HIDDEMANN, W ;
KOLB, HJ ;
LOFFLER, H ;
MARMONT, AM ;
MASCHMEYER, G ;
RIMM, AA ;
ROZMAN, C ;
SOBOCINSKI, KA ;
SPECK, B ;
THIEL, E ;
WEISDORF, DJ ;
ZWAAN, FE ;
BORTIN, MM .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (01) :13-18
[4]   Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT:: a GOELAMS trial [J].
Hunault, M ;
Harousseau, JL ;
Delain, M ;
Truchan-Graczyk, M ;
Cahn, JY ;
Witz, F ;
Lamy, T ;
Pignon, B ;
Jouet, JP ;
Garidi, R ;
Caillot, D ;
Berthou, C ;
Guyotat, D ;
Sadoun, A ;
Sotto, JJ ;
Lioure, B ;
Casassus, P ;
Solal-Celigny, P ;
Stalnikiewicz, L ;
Audhuy, B ;
Blanchet, O ;
Baranger, L ;
Béné, MC ;
Ifrah, N .
BLOOD, 2004, 104 (10) :3028-3037
[5]   Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia [J].
Jándula, BM ;
Nomdedeu, J ;
Marín, P ;
Vivancos, P .
BONE MARROW TRANSPLANTATION, 2001, 27 (02) :225-227
[6]   The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia [J].
Lee, S ;
Kim, YJ ;
Min, CK ;
Kim, HJ ;
Eom, KS ;
Kim, DW ;
Lee, JW ;
Min, WS ;
Kim, CC .
BLOOD, 2005, 105 (09) :3449-3457
[7]  
Martino R, 2003, HAEMATOLOGICA, V88, P555
[8]   Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia [J].
Matsue, K ;
Tabayashi, T ;
Yamada, K ;
Takeuchi, M .
BONE MARROW TRANSPLANTATION, 2002, 29 (01) :63-66
[9]   Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen [J].
Mohty, M ;
Bay, JO ;
Faucher, C ;
Choufi, B ;
Bilger, K ;
Tournilhac, O ;
Vey, N ;
Stoppa, AM ;
Coso, D ;
Chabannon, C ;
Viens, P ;
Maraninchi, D ;
Blaise, D .
BLOOD, 2003, 102 (02) :470-476
[10]   Drug therapy - Treatment of acute lymphoblastic leukemia [J].
Pui, CH ;
Evans, WE .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (02) :166-178